AZGP1作为局限期前列腺癌生物标志物的前瞻性多中心III期验证研究
本研究为多中心前瞻性III期验证研究,对347例根治性前列腺切除术标本行AZGP1免疫组化检测,评估其预后价值。结果显示低/缺失AZGP1表达独立预测生化复发、转移及前列腺癌特异性生存差,并在III期队列中验证,纳入现有风险模型可提高判别能力。
要点
- 低/缺失AZGP1表达独立预测局限期前列腺癌生化复发、转移及特异性生存差。
- III期队列验证:低/缺失AZGP1表达与BRFS(HR 1.9)和MFS(HR 2.0)独立相关。
- AZGP1纳入现有预后风险模型可改善判别能力。
核心结论
- 前瞻性III期验证表明低/缺失AZGP1表达在局限期前列腺癌中具有独立预后价值。
- 本研究为将该生物标志物纳入临床实践提供了有力证据。
研究设计与样本
- 多中心前瞻性III期研究,纳入347例根治性前列腺切除术标本。
- AZGP1状态由NATA认证实验室通过免疫组化检测,评分纳入含既定预后因素的多变量模型。
- 主要终点为生化复发无生存(BRFS),次要终点为无转移生存(MFS)和前列腺癌特异性生存(PCSS)。
- 同时报告既往II期研究的扩展随访结果。
主要发现
- II期队列中位随访15.8年,低/缺失AZGP1表达为BRFS差(HR 1.4;95%CI 1.1-1.9;P=0.03)、MFS差(HR 2.8;95%CI 1.2-6.6;P=0.02)和PCSS差(HR 3.8;95%CI 1.5-9.5;P=0.005)的独立预测因子。
- III期队列验证:低/缺失AZGP1表达独立预测BRFS(HR 1.9;95%CI 1.1-3.3;P=0.02)和更短MFS(HR 2.0;95%CI 1.1-3.4;P=0.02)。
- AZGP1纳入现有预后风险模型可提高判别价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancers (PCs) with similar characteristics at the time of diagnosis can have very different disease outcomes. Conventional biomarkers of PC still lack precision in identifying individuals at high risk of PC recurrence. While many candidate biomarkers are proposed in the literature, few are in clinical practice as they lack rigorous validation. This study prospectively enrolled an independent phase III cohort to evaluate the clinical utility of zinc-alpha 2-glycoprotein (AZGP1) as a prognostic biomarker in localized PC. PATIENTS AND METHODS: In our multicentre, prospective phase III study, AZGP1 status in 347 radical prostatectomy specimens was assayed by immunohistochemistry in a NATA-accredited laboratory. The AZGP1 score was assessed in a multivariable model incorporating established prognostic factors. We also report extended outcomes from our previous phase II study. The primary endpoint was biochemical relapse-free survival (BRFS). Secondary endpoints were metastasis-free survival (MFS) and PC-specific survival (PCSS). RESULTS: In the phase II cohort, with a median follow-up of 15.8 years, low/absent AZGP1 expression was an independent predictor of poor BRFS (HR, 1.4; 95% CI, 1.1-1.9; P = 0.03), MFS (HR, 2.8; 95% CI, 1.2-6.6; P = 0.02) and PCSS (HR, 3.8; 95% CI, 1.5-9.5; P = 0.005). These results were validated in our prospective phase III cohort. Low/absent AZGP1 expression independently predicted for BRFS (HR, 1.9; 95% CI, 1.1-3.3; P = 0.02), with shorter MFS (HR, 2.0; 95% CI, 1.1-3.4; P = 0.02). AZGP1 improved the discriminatory value when incorporated into existing prognostic risk models. CONCLUSION: Our study provides prospective phase III validation that absent/low AZGP1 expression provides independent prognostic value in PC. This study provides robust evidence for the incorporation of this biomarker into clinical practice.
引用
- Zhang AY, Grogan JS, Mahon KL, et al. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. Ann Oncol. 2017. PMID: 28486686. doi:10.1093/annonc/mdx247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。